![Zimmer Biomet Holdings, Inc. Website](https://cdn.finchat.io/264048.png)
Zimmer Biomet Holdings, Inc.
NYSE-ZBH
Company Overview
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Name
Zimmer Biomet Holdings, Inc.
CEO
Mr. Ivan Tornos
Website
www.zimmerbiomet.com
Sector
Health Care Equipment and Supplies
Year Founded
1927
Profile
Market Cap
$21.28B
EV
$26.9B
Shares Out
203.65M
Revenue
$7,524.8M
Employees
18,000
Margins
Gross
71.79%
EBITDA
33.5%
Operating
20.68%
Pre-Tax
13.57%
Net
13.25%
FCF
13%
Returns (5Yr Avg)
ROA
2.04%
ROTA
7.56%
ROE
3.78%
ROCE
6.29%
ROIC
5.6%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
$126.81
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
$420.1M
Net Debt
$5,614.5M
Debt/Equity
0.47
EBIT/Interest
7.66
Growth (CAGR)
Rev 3Yr
0.65%
Rev 5Yr
-0.9%
Rev 10Yr
4.91%
Dil EPS 3Yr
2.99%
Dil EPS 5Yr
22.19%
Dil EPS 10Yr
0.53%
Rev Fwd 2Yr
4.59%
EBITDA Fwd 2Yr
6.28%
EPS Fwd 2Yr
6.99%
EPS LT Growth Est
7.09%
Dividends
Yield
—
Payout
19.92%
DPS
$0.96
DPS Growth 3Yr
—
DPS Growth 5Yr
—
DPS Growth 10Yr
1.34%
DPS Growth Fwd 2Yr
0.67%